# psoriasis - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 2
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 66425
- Completion tokens: 50427
- Reasoning tokens: 8520
- Total tokens: 116852
- API requests reported: 5
- Elapsed seconds: 197.078
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1150.303
- Question handoff seconds: 1163.566
- Final benchmark system: E2seq; file rank 1/5; original repeat 2; model vendor: MiniMax

---
<think>The user wants a comprehensive biological interpretation of transcriptomic data comparing psoriatic lesional skin versus normal control skin. I have 100 genes with log2FC, P value, and FDR values. 90 are upregulated, 10 are downregulated. The data is heavily skewed toward upregulation with very strong statistical significance (FDR values reaching e-146).

Let me organize what I have:

**Upregulated genes (90)** - Notable clusters:
1. **IL-36 cytokines/IL-20 family**: IL36A (log2FC=11.37), IL36G (5.68), IL36RN (3.00), IL19 (7.58), IL20 (5.67), IL26 (4.36)
2. **Antimicrobial peptides**: DEFB4A (11.18), DEFB4B (11.03), DEFB103A (5.76), DEFB103B (5.75), PI3 (9.24), S100A7 (7.09), S100A7A (9.83), S100A8 (7.73), S100A12 (8.33)
3. **Cornified envelope/Small proline-rich proteins**: SPRR2A (7.31), SPRR2B (6.38), SPRR2D (5.92), SPRR2E (3.99), SPRR2F (7.22), SPRR2G (4.75), SPRR3 (7.18), LCE3A (8.30), LCE3D (5.31)
4. **Keratin/epidermal differentiation**: KRT6A (4.30), SERPINB3 (6.74), SERPINB4 (9.12), SERPINB11 (4.47), SERPINB13 (3.09), PI3
5. **Lipid metabolism/transport**: FABP5 (3.65), AKR1B10 (6.27), AKR1B15 (5.23), PLA2G4D (4.61), PLA2G4E (2.47), SLC6A14 (4.47), ABCG4 (4.75)
6. **Gap junctions**: GJB2 (4.42), GJB6 (3.02)
7. **Chemokines/CXCL/CXCR**: CXCL13 (5.89), CXCR2 (2.70), HRH2 (3.27)
8. **Proteases/serine proteases**: KLK13 (4.05), TMPRSS11D (7.75), PRSS27 (4.24), HABP2 (4.19), PLBD1 (2.08)
9. **Keratinocyte proliferation**: CDK5R1 (2.35), CCNE1 (2.56), RRM2 (2.72), TPBG (1.86)
10. **Signaling regulators**: TNIP3 (7.28), ZC3H12A (3.85), IRAK2 (2.08), PRKCQ (2.88)
11. **Other notable**: WNT5A (2.53), HPSE (2.92, heparanase), CD274 (3.44, PD-L1), VNN3P (8.28), ADGRF1 (6.64), GDA (guanine deaminase, 5.90), KYNU (kynureninase, 4.42), WNT5A

**Downregulated (10)**: 
- LOC107984452 (-6.25)
- BTC (-4.30)
- LOC105371988 (-4.10)
- CYP2W1 (-4.70)
- LINC02660 (-3.90)
- LOC107984005 (-4.27)
- SAPCD1 (-2.94)
- UGT3A2 (-4.59)
- WAKMAR1 (-5.63)
- SAPCD1-AS1 (-2.84)

GO/KEGG from RAG:
- Response To Lipopolysaccharide
- Epidermis Development
- Antimicrobial Humoral Response
- IL-17 signaling pathway
- Cytokine-cytokine receptor interaction
- Staphylococcus aureus infection

This is a very classic psoriasis transcriptomic signature. Let me structure the answer:

**1. Overall biological interpretation:**
The data shows a stereotypical psoriatic lesional skin signature with massive upregulation of:
- IL-36/IL-20 cytokine family
- Antimicrobial peptides (β-defensins, S100 proteins, PI3/elafin)
- Cornified envelope components (SPRR, LCE)
- Keratinocyte differentiation/proliferation
- Lipid metabolic enzymes
- Inflammatory signaling

**2. Core biological programs (5 max):**
1. **IL-36/IL-17/IL-20 axis amplification** (innate alarmins/keratinocyte-th17 feedback)
2. **Antimicrobial defense program** (β-defensins, S100 calprotectin, PI3/elafin)
3. **Epidermal cornified envelope & keratinocyte hyperproliferation** (SPRR, LCE, KRT6, SERPINB)
4. **Lipid metabolism & barrier remodeling** (FABP5, AKR1B10/15, PLA2G4, ABCG4, SLC6A14)
5. **Immune cell recruitment & chemokine signaling** (CXCL13, CXCR2, neutrophil-attractant)

**3. Key genes (up to 10):**
- IL36A/G (highest FC)
- DEFB4A/B (β-defensin 2)
- PI3 (elafin)
- S100A7/A7A/A8/A12 (calprotectin/alarmin)
- SPRR2A-F family
- SERPINB3/B4
- KRT6A
- CXCL13
- TNIP3

**4. Validation priorities (5 max):**
1. IL-36 axis as therapeutic target (supported by FDA-approved IL-36R inhibitor, spesolimab)
2. DEFB4A/PI3 as biomarkers for IL-17/NET activity
3. Cornified envelope hyperactivation (SPRR/LCE) as a marker of disturbed epidermal differentiation
4. FABP5/AKR1B10 - lipid metabolic reprogramming
5. CD274 (PD-L1) - immune checkpoint in keratinocytes (a different angle)

**5. Evidence grounding:** distinguish input vs pathway/literature

**6. Limitations:** cell composition (neutrophil influx), treatment exposure, plaque vs uninvolved, etc.

Let me write a careful, evidence-grounded response. I should focus on:
- Direction-consistent story from log2FC
- Concordance with known psoriasis programs
- Distinguishing between what's established, supported, and exploratory
- Being careful about therapeutic extrapolation
- Not over-claiming

The retrieval includes some European PMC/PubMed records - I should cite the one about psoriasis biomarkers (PMID 40560938).

Let me write the full response now. I'll be concise but thorough.</think>

# Multidimensional Interpretation: Psoriatic Lesional Skin vs Normal Skin

## 1. Overall Biological Interpretation

The uploaded gene list is dominated by a strongly directional, very strongly significant upregulation signal (90 of 100 genes up; log2FC range ~1.86–11.37; FDR minimum 2.6e-146), which is the canonical molecular signature of an active psoriatic plaque. The 10 downregulated genes are mostly uncharacterized loci (LOC entries, lincRNAs, SAPCD1/AS1) or contextually interpretable loci (BTC, CYP2W1, UGT3A2, WAKMAR1).

Synthesizing across all genes, the data depict a coordinated, mutually reinforcing triad:

1. **Hyperactivated innate epithelial immunity** — a coordinated burst of IL-36 family cytokines (IL36A, IL36G, IL36RN), IL-20 family cytokines (IL19, IL20, IL26), and pattern-recognition response genes (S100A8/A12/A7/A7A, TNIP3, ZC3H12A, IRAK2).
2. **Antimicrobial/barrier defense amplification** — massive induction of β-defensins (DEFB4A/B, DEFB103A/B), the antileukoproteinase PI3 (elafin), SERPINB3/B4/B11/B13, and serine proteases (KLK13, TMPRSS11D, PRSS27).
3. **Keratinocyte hyperproliferation and aberrant epidermal differentiation** — cornified envelope components (SPRR2A–G, SPRR3, LCE3A/D), KRT6A, FABP5, AKR1B10/15, and cell-cycle genes (CCNE1, RRM2, CDK5R1).

The aggregate picture is a self-amplifying keratinocyte-immune circuit centered on the IL-17/IL-22–IL-36/IL-20 axis, with neutrophilic and lipid-peroxidation–type antimicrobial responses layered on top, and a downstream epidermal remodeling signature. The 10 downregulated genes do not, as a group, obviously counter the dominant signal; most are likely passenger transcriptional shifts accompanying the inflammatory remodeling rather than a coherent counter-program.

---

## 2. Core Biological Programs

### Program A — IL-36/IL-20 family cytokine amplification
- **Direction:** Up.
- **Major genes:** IL36A (log2FC=11.37), IL36G (5.68), IL36RN (3.00), IL19 (7.58), IL20 (5.67), IL26 (4.36).
- **Standard annotation:** Reactome "Interleukin-20 family signaling" (R-HSA-8854691); KEGG "Cytokine–cytokine receptor interaction"; GO "inflammatory response / JAK-STAT signaling."
- **Why this set:** IL36A and IL36G are the largest absolute effect sizes in the entire table (log2FC 11.37 and 5.68) and IL36RN (the natural antagonist) is also up, indicating active feed-forward and feedback regulation. The IL-20 family receptors (IL19, IL20, IL26) are co-expressed, and STRING edges link IL36A/G/RN to IL1RAP. Reactome vector evidence also places IL19 and IL26 in IL-20 family signaling.
- **Evidence strength:** Direct dataset (very strong, FDR~3.5e-62 to 1.7e-98) is concordant with well-established psoriasis biology (positive regulation of IL-36 by IL-17/IL-22). Independent statistical replication was not supplied; confidence in this being a central program is supported, not proven, by external evidence.
- **Limitations:** The signal may partially reflect increased keratinocyte mass rather than per-cell activation. IL36RN induction could be compensatory; IL-36 pathway blockade studies (e.g., spesolimab) are needed to confirm causal necessity.

### Program B — Antimicrobial peptide and neutrophil-recruitment response
- **Direction:** Up.
- **Major genes:** DEFB4A (11.18), DEFB4B (11.03), DEFB103A (5.76), DEFB103B (5.75), PI3/elafin (9.24), S100A7 (7.09), S100A7A (9.83), S100A8 (7.73), S100A12 (8.33), CXCL13 (5.89), CXCR2 (2.70).
- **Standard annotation:** GO "Antimicrobial humoral response" (GO:0019730); KEGG "IL-17 signaling pathway"; "Staphylococcus aureus infection" (the latter reflects how psoriatic lesions share a signature with staphylococcal colonization, not a claim of infection).
- **Why this set:** β-defensin 4 (DEFB4A/B) and PI3/elafin are the highest-FC antimicrobial effectors in psoriatic keratinocytes and are direct IL-17/IL-22 transcriptional targets. The S100A8/A12 (calprotectin) and S100A7/A7A (koebnerisin) proteins are canonical "alarmins." CXCL13 and CXCR2 indicate recruitment of B/T cells and neutrophils, respectively.
- **Evidence strength:** Strong direct dataset signal (FDR ≤ 2.2e-69). Consistent with replicated published literature (e.g., PMID 40560938, an integrated WGCNA/LASSO psoriasis biomarker study in the retrieved literature set). Independent cohort replication was not performed.
- **Limitations:** DEFB4/PI3 induction is also seen in wound healing and other Th17 skin conditions; the signal may not be fully specific to psoriasis.

### Program C — Epidermal cornified envelope and hyperproliferation
- **Direction:** Up.
- **Major genes:** SPRR2A (7.31), SPRR2B (6.38), SPRR2D (5.92), SPRR2E (3.99), SPRR2F (7.22), SPRR2G (4.75), SPRR3 (7.18), LCE3A (8.30), LCE3D (5.31), KRT6A (4.30), SERPINB3 (6.74), SERPINB4 (9.12), SERPINB11 (4.47), SERPINB13 (3.09), PI3 (9.24); proliferation: CCNE1 (2.56), RRM2 (2.72), CDK5R1 (2.35), TPBG (1.86).
- **Standard annotation:** Reactome "Formation of the cornified envelope" (R-HSA-6809371); GO "Epidermis development" (GO:0008544); Hallmark "Epidermal differentiation."
- **Why this set:** Six small proline-rich proteins (SPRR2A/B/D/E/F/G), three LCE3 paralogs, four SERPINB paralogs, KRT6A, and PI3 form a contiguous structural/differentiation module driving the thickened, parakeratotic plaque. The CCNE1/RRM2/CDK5R1/TPBG quartet is consistent with hyperproliferative keratinocyte cycling.
- **Evidence strength:** Direct dataset signal extremely strong for all 12+ genes in the Reactome cornified envelope module. Network evidence (STRING) supports multiple edges within SPRR and SERPINB families. Limitations: some redundancy in this gene set (multiple paralogs), and most individual SPRR genes are not biologically validated beyond expression.
- **Limitations:** Some of these genes (e.g., PI3/elafin) overlap program A/B; assignment to a single program is partly arbitrary. The proliferation signature is modest (log2FC ~2–3) and could partly reflect cell-composition differences.

### Program D — Lipid metabolic reprogramming and barrier chemistry
- **Direction:** Up.
- **Major genes:** AKR1B10 (6.27), AKR1B15 (5.23), FABP5 (3.65), PLA2G4D (4.61), PLA2G4E (2.47), ABCG4 (4.75), SLC6A14 (4.47), HPSE (2.92).
- **Standard annotation:** GO "lipid metabolic process"; Reactome "Metabolism of lipids"; KEGG "Arachidonic acid metabolism."
- **Why this set:** Two aldo-keto reductases (AKR1B10/15) and two phospholipases (PLA2G4D/E) suggest altered lipid peroxide and eicosanoid chemistry in lesional skin; FABP5 carries fatty acids in hyperplastic keratinocytes; ABCG4 and SLC6A14 reflect altered transport of lipids/amino acids. HPSE (heparanase) reflects ECM remodeling.
- **Evidence strength:** Direction consistent with published transcriptomic studies of psoriasis (AKR1B10 induction in keratinocytes is recurrent in the literature). The set is smaller in cross-replicate recurrence than Programs A/B, and the network/pathway evidence here is partly derived from generic GO annotations rather than disease-specific datasets.
- **Limitations:** Weaker literature grounding for AKR1B15 specifically (more often linked in retrieved literature to lung cancer chemoresistance — PMID 39017606 — not directly to psoriasis). Independent statistical replication not provided.

### Program E — Negative regulatory/immune-checkpoint adaptation
- **Direction:** Mixed (mostly up with some contextual down).
- **Major genes up:** TNIP3 (7.28; also a GWAS psoriasis locus), ZC3H12A (3.85; Monocyte chemotactic protein–induced protein / Regnase-1), IRAK2 (2.08), CD274 (3.44; PD-L1).
- **Major genes down:** BTC (-4.30; betacellulin), SAPCD1 (-2.94, candidate suppressor).
- **Standard annotation:** GO "negative regulation of NF-κB"; Reactome "TNF signaling."
- **Why this set:** TNIP3 is a known negative regulator of NF-κB and a GWAS-supported psoriasis susceptibility gene. ZC3H12A is an mRNA decay activator that limits inflammatory cytokine transcripts. CD274 (PD-L1) upregulation may dampen keratinocyte-intrinsic immune activity. These suggest an embedded negative-feedback attempt, partially overlapping with sustained positive drive.
- **Evidence strength:** Direct dataset signal strong for TNIP3 (FDR 2.8e-83) and moderate for CD274 and ZC3H12A; lower-confidence program overall and partially overlapping with Program A. External evidence shows TNIP3 is a recognized GWAS gene; PD-L1 in psoriatic keratinocytes is discussed in retrieved literature (PMID 38354028, anti-CD274 targeting).
- **Limitations:** Program E is partly an inference from the dataset rather than a coherent ontological module. Weaker literature grounding than A/B/C.

---

## 3. Key Genes and Interaction Modules

I focus on the strongest integrative candidates, distinguishing interaction type explicitly.

1. **IL36A (log2FC=11.37; up)** — Highest-FC cytokine, anchor of Program A. STRING edges to IL1RAP (co-expression/pathway co-membership, Reactome "Interleukin-20 family signaling"); proposed relationship: signal via IL-36R to amplify keratinocyte chemokine/AMP production.
2. **IL36G (5.68) and IL36RN (3.00)** — Sister cytokine and antagonist. STRING edges among IL36A/G/RN to IL1RAP; pathway co-membership.
3. **DEFB4A / DEFB4B (~11.1 / 11.0; up)** — β-defensin 2. STRING edges to CCR6 (pathway co-membership in antimicrobial response). Direct IL-17A target.
4. **PI3 (9.24; up)** — Elafin/SKALP; direct readout of epidermal-immune activation with anti-NE activity. Co-membership with SERPINB family in neutrophil protease inhibition.
5. **S100A8 / S100A12 (~7.7 / 8.3; up)** — Calprotectin components, abundant in neutrophil-infiltrated psoriatic plaque. STRING edges within S100A7/S100A12/FABP5/SERPINB3/B4 indicate co-expression; not direct physical interaction unless specifically demonstrated.
6. **SPRR2 family (A,B,D,E,F,G) and LCE3A/3D** — Cornified envelope module. STRING edges within SPRR paralogs are pathway co-membership within the same Reactome module; physical interaction evidence is not specifically demonstrated in the retrieved STRING evidence for most SPRR2-LCE3 pairs.
7. **SERPINB3 / SERPINB4 (6.74 / 9.12; up)** — Squamous-cell serpin family. STRING co-expression and co-membership; proposed regulatory role in controlling neutrophil proteases. Independent target of multiple proteomic psoriasis studies.
8. **KRT6A (4.30) and KRT-cluster remodeling** — Hallmark of hyperplastic, wound-like keratinocyte state. Co-expression rather than direct physical interaction.
9. **TNIP3 (7.28) and ZC3H12A (3.85)** — Negative-feedback regulators. STRING/Reactome suggest pathway co-membership in NF-κB termination.
10. **CD274 / PD-L1 (3.44; up)** — Immune-checkpoint ligand induced in inflamed keratinocytes. STRING co-expression with IL-36/IL-17 targets; not necessarily a direct physical interaction.

*Note: most of the network "edges" retrieved here are pathway co-membership or co-expression from STRING/Reactome; they should not be reported as direct protein-protein binding unless confirmed by an interaction-source record (IntAct/BioGRID).*

---

## 4. Validation Priorities

### 4.1 IL-36 axis as a therapeutic / mechanistic target — *Therapeutic target / mechanistic hypothesis*
- **Priority rationale:** IL36A/G are the two highest-FC genes in the dataset (log2FC 11.37 / 5.68; FDR 1.7e-98 / 1.4e-90); IL36RN is also induced. The IL-36 pathway already has clinically tested antagonists (e.g., spesolimab for generalized pustular psoriasis).
- **Evidence:** Very strong direct dataset signal.
- **External:** Published primary trial literature and Reviews on IL-36R blockade; consistent with broader psoriasis IL-17 / IL-22 upstream.
- **Next step:** Stratify lesional biopsies by IL36A/G expression and test anti-IL-36 vs anti-IL-17/IL-23 response; measure neutrophil chemokines as proximal PD markers.
- **Classification:** *Supported hypothesis* — direct dataset strength and external clinical data are consistent.

### 4.2 DEFB4A / PI3 as a composite biomarker of IL-17 / IL-36 activity in skin — *Biomarker*
- **Priority rationale:** Both have very high log2FC (11.18 / 9.24) and FDR ≤ 2.2e-69; they are canonical readouts of IL-17A/IL-22 signaling and are easily measurable in serum (DEFB4B/PI3 as protein) or RNA.
- **Evidence:** Direct dataset (very strong).
- **External:** Recurrent use in WGCNA/LASSO psoriasis biomarker pipelines (PMID 40560938).
- **Next step:** qPCR/ELISA validation in independent lesional/non-lesional cohorts; correlate with PASI/BSA and with serum IL-17A/IL-22.
- **Classification:** *Supported hypothesis.*

### 4.3 SPRR2 / LCE3 / SERPINB cornified-envelope activation as a transcriptional remodeling signature — *Mechanistic hypothesis / biomarker*
- **Priority rationale:** Twelve of the top 100 genes are members of this module, making it a coherent candidate for a molecular barometer of lesional epidermal remodeling.
- **Evidence:** Strong direct dataset signal; Reactome cornified envelope recurrence.
- **External:** Partial literature on individual genes (e.g., KRT6A in alopecia areata — PMID 42216026).
- **Next step:** Stratify by histological acanthosis; test whether SERPINB/SPRR induction precedes or follows AMP/IL-36 induction in time-course models (organoid/psoriatic skin substitute).
- **Classification:** *Exploratory hypothesis.* — the module is highly recurrent in the dataset but its functional significance in plaque pathology is less well-validated.

### 4.4 CD274 / PD-L1 induction in keratinocytes — *Mechanistic / therapeutic hypothesis*
- **Priority rationale:** log2FC 3.44, FDR 1.8e-63, suggesting keratinocyte-intrinsic PD-L1 upregulation that may shape local T-cell responses. Retrieved literature (PMID 38354028) discusses anti-CD274 bispecific antibodies in inflammatory disease contexts.
- **Evidence:** Direct signal; external context on PD-L1 in autoimmune skin.
- **Next step:** IHC for PD-L1 in lesional/uninvolved biopsies; assess correlation with lesional T-cell infiltrate.
- **Classification:** *Exploratory hypothesis* — single moderately-FC gene; do not interpret as evidence that anti-PD-1/PD-L1 therapy has a known role in psoriasis (in fact, immune-checkpoint inhibitors can *induce* psoriasis-like eruptions).

### 4.5 Cell-composition confounding of the IL-17A/IL-22/AMP signature — *Confounding / composition check*
- **Priority rationale:** S100A8/A12, CXCL13, CXCR2, DEFB4A, and PI3 are enriched in neutrophils, dendritic cells, and lymphocytes. Neutrophil influx into psoriatic plaques is well-documented and could account for a portion of the "lesional" signal.
- **Evidence:** Many of the largest-FC genes are neutrophil-associated.
- **Next step:** Deconvolve the bulk RNA-seq signature (e.g., CIBERSORTx / BisqueRNA) against matched scRNA-seq references; or measure neutrophil counts in biopsies and regress against gene expression.
- **Classification:** *Confounding-check mechanistic hypothesis* — important for both Program A and Program B interpretation.

---

## 5. Evidence Grounding Summary

- **Direct (this dataset):** All log2FC, P, and FDR values come from the user-supplied table only. Independent cohort replication was *not supplied* in the inputs.
- **Pathway/ontology evidence:** KEGG and Reactome recurrences (cornified envelope, IL-17 signaling, antimicrobial humoral response, IL-20 family signaling) are from the RAG evidence pack and serve as annotation, not new statistics.
- **Network evidence:** STRING-reported edges are co-expression/co-membership in most cases; only the IL1RAP–IL36 cluster and IL10RB/IL20RA edges show high interaction confidence, but those are interaction evidence, not statistics.
- **GWAS/disease-association:** TNIP3 is the best-established GWAS psoriasis locus (program E); IL36RN deficiency underlies generalized pustular psoriasis (DITRA) and is broadly considered confirmed genetic evidence.
- **Therapeutic evidence:** IL-36R blockade (spesolimab, imsidolimab) is clinically validated for GPP; anti-IL-17 (secukinumab, ixekizumab, brodalumab), anti-IL-23 (risankizumab, guselkumab), and anti-TNF are validated for plaque psoriasis. The dataset does not include pharmacogenomic data, so we cannot claim prediction of response.
- **Independence caveat:** Many of these external sources overlap (e.g., Reactome and STRING share curated literature bases; the WGCNA/LASSO biomarker paper and the Reactome cornified envelope module partially share references). They are not strictly independent.

---

## 6. Limitations and Alternative Explanations

1. **Cellular composition and infiltrating neutrophils.** Lesional psoriatic skin contains Krt6+/Ki-67+ keratinocyte hyperplasia plus a dense infiltrate of neutrophils, dendritic cells, and T cells. Many of the top-FC genes (S100A8/A12, DEFB4A/B, CXCL13, CXCR2) are markers of those infiltrates rather than resident keratinocytes; expression changes may reflect shifts in cell mix rather than per-cell transcriptional change.
2. **Plaque vs uninvolved and disease severity.** The contrast is lesional vs normal; non-lesional psoriatic skin (also molecularly abnormal) was not included. Effect sizes may therefore conflate disease activity with cell-composition shifts, and may differ across mild vs severe disease.
3. **Treatment exposure is unknown.** If any biopsies were from patients on biologics or topical steroids, the keratinocyte-AMP axis would be partially normalized; unexposed vs treated comparator cohorts would yield different magnitudes.
4. **Batch/platform effects and gene-level summarization.** Without batch correction QC and probe-level checks, some very large FC values for lincRNAs (LOC*, LINC*, KLHDC7B-DT, CERNA2, etc.) may reflect annotation artifacts rather than true biology; these should be viewed as exploratory.
5. **Association vs causation.** Even very large FC values do not establish that any of these programs drive the disease. Functional perturbation (e.g., IL-36R blockade, keratinocyte-specific ZC3H12A ablation) is required to move from association to mechanism.

---

## Bottom Line

The molecular phenotype is that of an active psoriatic plaque: massive induction of the IL-36/IL-20 cytokine family, antimicrobial peptides (β-defensins, PI3/elafin, S100 alarmins), and cornified-envelope / keratinocyte-proliferation genes, with concurrent negative-feedback (TNIP3, ZC3H12A, CD274) and lipid-metabolic (AKR1B10/15, FABP5, PLA2G4D/E) reprogramming. The IL-36 axis and the DEFB4A/PI3 AMP pair are the strongest direct signals and the most defensible biomarker/therapeutic candidates, but causal interpretation requires functional perturbation and independent cohort replication, neither of which is supplied here.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=7, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 91/100 selected items (records returned); cbioportal 91/100 selected items (records returned); chembl 11/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 44/100 selected items (partially returned; some queries failed); europepmc 848 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 76/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 79/100 selected items (records returned); mygene 100/100 selected items (records returned); omnipath 36/100 selected items (records returned); opentargets 90/100 selected items (records returned); pubmed 669 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 80/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 2/100 selected items (records returned); hmdb 25/100 selected items (records returned); string 78/100 selected items (records returned); trrust 17/100 selected items (records returned)
